PUBLISHER: The Business Research Company | PRODUCT CODE: 1939309
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939309
Automated immunoassay analyzers are sophisticated laboratory instruments designed to conduct immunoassays with minimal human input. These analyzers automate the detection and measurement of specific proteins, hormones, and other substances in biological samples, enhancing accuracy and efficiency in diagnostic testing. They are commonly used in clinical laboratories for disease diagnosis, monitoring, and research purposes.
The primary types of automated immunoassay analyzers include immunofluorescence, chemiluminescence, enzyme-linked immunosorbent assay (ELISA), multiplexed assay systems, and radioimmunoassay. Immunofluorescence is a technique that employs fluorescent-labeled antibodies to identify specific antigens in biological samples. These analyzers are applied in various fields, including infectious diseases, endocrinology, drug monitoring, cardiology, oncology, and allergy testing. They are utilized by hospitals, diagnostic laboratories, research and academic institutions, as well as pharmaceutical and biotechnology companies.
Tariffs are influencing the automated immunoassay analyzers market by increasing costs for precision optical components, electronic modules, assay reagents, and instrument assemblies sourced across cross-border manufacturing networks. The impact is most significant in chemiluminescence and multiplexed assay systems, as well as analyzer production activities concentrated in Asia-Pacific and parts of Europe where component imports are tariff-sensitive. Hospitals, diagnostic laboratories, and pharmaceutical and biotechnology company end-user segments are facing higher procurement and installation costs due to elevated instrument pricing. However, tariffs are also encouraging regional assembly, localized reagent manufacturing, and strategic supplier diversification, which may strengthen supply resilience and stimulate domestic production capacity over time.
The automated immunoassay analyzers market research report is one of a series of new reports from The Business Research Company that provides automated immunoassay analyzers market statistics, including automated immunoassay analyzers industry global market size, regional shares, competitors with a automated immunoassay analyzers market share, detailed automated immunoassay analyzers market segments, market trends and opportunities, and any further data you may need to thrive in the automated immunoassay analyzers industry. This automated immunoassay analyzers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The automated immunoassay analyzers market size has grown rapidly in recent years. It will grow from $23.09 billion in 2025 to $26.39 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to expansion of centralized clinical laboratories, growth in routine immunoassay testing volumes, increasing disease screening programs, early automation of laboratory workflows, adoption of immunoassay systems for infectious disease monitoring.
The automated immunoassay analyzers market size is expected to see rapid growth in the next few years. It will grow to $44.93 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to rising chronic and endocrine disorder testing needs, growing oncology and biomarker testing, demand for faster turnaround diagnostic results, increasing integration of automated platforms in research labs, expansion of pharmaceutical and biotech r&d testing applications. Major trends in the forecast period include growing demand for high-throughput diagnostic testing, increased adoption in infectious disease and endocrinology testing, expansion of automated testing in research and academic laboratories, rising utilization in therapeutic drug monitoring and oncology diagnostics, standardization of laboratory workflows to improve testing efficiency.
The increasing number of hospitals is expected to propel the growth of the automated immunoassay analyzers market going forward. Hospitals are healthcare institutions that provide medical, surgical, and diagnostic services to patients requiring routine treatment or emergency care, supported by specialized infrastructure and healthcare professionals. The global rise in the number of hospitals is driven by growing healthcare demand from expanding and aging populations, along with increased investments in healthcare infrastructure. Automated immunoassay analyzers support hospitals by enabling high-throughput, accurate, and rapid diagnostic testing for a wide range of diseases, improving clinical efficiency and patient outcomes. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the United States increased to 6,129 in 2023 from 6,093 in 2022, reflecting a 0.59% growth. Therefore, the increasing number of hospitals is driving the growth of the automated immunoassay analyzers market.
Leading companies in the automated immunoassay analyzer market are focusing on developing advanced products, such as compact immunoassay analyzers, to gain a competitive edge. These compact devices are designed for conducting immunoassay tests to detect specific biomarkers in biological samples and offer convenience and efficiency in various healthcare settings, especially where space and mobility are constraints. For instance, in July 2023, Siemens Healthineers, a Germany-based healthcare company, introduced the Atellica CI Analyzer. This compact system combines immunoassay and clinical chemistry testing into a single platform, addressing the growing demand for versatile and efficient testing solutions. The Atellica CI Analyzer features random access sampling, micro-volume aspiration, and automated maintenance and quality control scheduling to enhance the consistency and predictability of sample processing times.
In July 2024, Roche, a Switzerland-based provider of diagnostics, pharmaceutical products, and point-of-care testing solutions, acquired LumiraDx's point-of-care technology for an undisclosed amount. With this acquisition, Roche aims to strengthen and decentralize its diagnostics portfolio by integrating a multi-assay point-of-care platform that combines immunoassay and clinical chemistry testing on a single system. This move supports Roche's strategic objective to expand access to rapid, near-patient diagnostics, particularly in primary care and low-resource settings. LumiraDx is a UK-based developer of a multi-assay point-of-care platform designed to deliver laboratory-quality results across immunoassay and clinical chemistry tests at the point of care.
Major companies operating in the automated immunoassay analyzers market are Roche Diagnostics AG, Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickinson and Company, Tosoh Corporation, bioMerieux SA, QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc, Qiagen NV, Werfen Group SA, DiaSorin SpA, Bio-Techne Corporation, Meril Life Sciences Private Limited, Randox Laboratories Ltd, Getein Biotech Inc, Aesku Diagnostics GmbH & Co KG, Carolina Liquid Chemistries Corporation, Chengdu Seamaty Technology Co Ltd, Hipro Biotechnology Co Ltd
North America was the largest region in the automated immunoassay analyzer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the automated immunoassay analyzers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the automated immunoassay analyzers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The automated immunoassay analyzers market consists of sales of sample handlers, reagents, incubation chambers, thermal printers, and wash stations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Automated Immunoassay Analyzers Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses automated immunoassay analyzers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for automated immunoassay analyzers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The automated immunoassay analyzers market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.